Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

589 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials.
Jank P, Karn T, van Mackelenbergh M, Lindner J, Treue D, Huober J, Engels K, Solbach C, Diebold K, Marmé F, Müller V, Schneeweiss A, Sinn HP, Fehm T, Schem C, Stickeler E, Fasching P, Budczies J, Felder B, Nekljudova V, Holtschmidt J, Untch M, Denkert C, Loibl S. Jank P, et al. Among authors: fehm t. Clin Cancer Res. 2024 Sep 3;30(17):3868-3880. doi: 10.1158/1078-0432.CCR-24-0459. Clin Cancer Res. 2024. PMID: 38837894 Clinical Trial.
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.
Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K. Riethdorf S, et al. Among authors: fehm t. Clin Cancer Res. 2010 May 1;16(9):2634-45. doi: 10.1158/1078-0432.CCR-09-2042. Epub 2010 Apr 20. Clin Cancer Res. 2010. PMID: 20406831 Clinical Trial.
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.
von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, Kreienberg R, Hilfrich J, Gerber B, Hanusch C, Fehm T, Strumberg D, Solbach C, Nekljudova V, Untch M; German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie-Brust investigators. von Minckwitz G, et al. Among authors: fehm t. Ann Oncol. 2011 Feb;22(2):301-6. doi: 10.1093/annonc/mdq350. Epub 2010 Jul 12. Ann Oncol. 2011. PMID: 20624784 Free article.
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.
Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Löhberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K. Fehm T, et al. Breast Cancer Res Treat. 2010 Nov;124(2):403-12. doi: 10.1007/s10549-010-1163-x. Epub 2010 Sep 22. Breast Cancer Res Treat. 2010. PMID: 20859679 Clinical Trial.
Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis.
Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Jückstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B. Janni W, et al. Among authors: fehm t. Clin Cancer Res. 2011 May 1;17(9):2967-76. doi: 10.1158/1078-0432.CCR-10-2515. Epub 2011 Mar 17. Clin Cancer Res. 2011. PMID: 21415211
Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.
Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B, Ortmann O, Fehm T, Rezai M, Mehta K, Loibl S; German Breast Group Investigators. Gerber B, et al. Among authors: fehm t. J Clin Oncol. 2011 Jun 10;29(17):2334-41. doi: 10.1200/JCO.2010.32.5704. Epub 2011 May 2. J Clin Oncol. 2011. PMID: 21537042 Clinical Trial.
Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.
Aktas B, Müller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg CR, Rack B, Schneeweiss A, Fehm T. Aktas B, et al. Among authors: fehm t. Gynecol Oncol. 2011 Aug;122(2):356-60. doi: 10.1016/j.ygyno.2011.04.039. Epub 2011 May 24. Gynecol Oncol. 2011. PMID: 21605893
The concordance rate between ER, PR and HER2 status of CTCs and the primary tumor was 29%, 25% and 53%, respectively (Fehm T et al., Breast Cancer Res Aug 10 2009, 11(4) pR59). Based on these results we studied blood samples of 193 metastatic breast cancer patients …
The concordance rate between ER, PR and HER2 status of CTCs and the primary tumor was 29%, 25% and 53%, respectively (Fehm T e …
589 results